Clinical Characteristics of Patients Who Had and Who Did Not Have Cardiac Death
| Characteristic | Did not have cardiac death (n = 152) | Had cardiac death (n = 56) | P |
|---|---|---|---|
| Age (y) | 68 ± 12 | 71 ± 10 | 0.066 |
| Sex, male | 91 (59.9%) | 39 (69.6%) | 0.258 |
| Ischemic etiology | 67 (44.1%) | 22 (39.3%) | 0.636 |
| NYHA (baseline), I/II/III/IV | 0/54/91/7 | 0/16/31/9 | 0.723 |
| NYHA (follow-up), I/II/III/IV | 34/63/54/1 | 6/23/27/0 | 0.860 |
| 123I-MIBG scintigraphy | |||
| Baseline % denervation | 58 ± 11 | 60 ± 7 | 0.239 |
| Baseline H/M ratio | 169 ± 19 | 158 ± 22 | 0.001 |
| Baseline WR (%) | 47 ± 10 | 53 ± 10 | <0.001 |
| Second % denervation | 48 ± 14 | 61 ± 13 | <0.001 |
| Second H/M ratio | 182 ± 22 | 158 ± 23 | <0.001 |
| Second WR (%) | 41 ± 11 | 57 ± 12 | <0.001 |
| Δ-% denervation | −10 ± 12 | 0 ± 11 | <0.001 |
| Δ-H/M ratio | 14 ± 16 | 0 ± 16 | <0.001 |
| Δ-WR (%) | −6 ± 11 | 4 ± 10 | <0.001 |
| Echocardiography | |||
| Baseline LVEDV (mL) | 181 ± 45 | 187 ± 34 | 0.401 |
| Baseline LVESV (mL) | 122 ± 41 | 133 ± 40 | 0.106 |
| Baseline LVEF (%) | 33 ± 8 | 30 ± 9 | 0.014 |
| Second LVEDV (mL) | 162 ± 50 | 187 ± 46 | 0.001 |
| Second LVESV (mL) | 101 ± 46 | 130 ± 52 | <0.001 |
| Second LVEF (%) | 40 ± 10 | 33 ± 11 | <0.001 |
| Δ-LVEDV (mL) | −19 ± 35 | 0 ± 24 | <0.001 |
| Δ-LVESV (mL) | −22 ± 34 | −3 ± 22 | <0.001 |
| Δ-LVEF (%) | 6 ± 8 | 3 ± 6 | 0.001 |
| Pharmacotherapy | |||
| ACE inhibitor | 102 (67.1%) | 35 (62.5%) | 0.621 |
| ARB | 103 (67.8%) | 31 (55.4%) | 0.105 |
| β-blocker | 75 (49.3%) | 17 (30.4%) | 0.018 |
| Spironolactone | 65 (42.8%) | 17 (30.4%) | 0.113 |
Values are mean ± SD or number followed by percentage in parentheses.